News

Register Now for OSCO’s 2019 Official Best of San Antonio Breast Cancer Symposium®

Posted on 2.20.2019

Date:    Saturday, April 6, 2019
Place:   OU Andrews Academic Tower, 800 Stanton L. Young Blvd., Oklahoma City, OK
Time:   8:00 AM –12:30 PM

Join OSCO for the Official Best of San Antonio Breast Cancer Symposium® designed … Read More “Register Now for OSCO’s 2019 Official Best of San Antonio Breast Cancer Symposium®”

AstraZeneca announces new CMS J-code assigned for IMFINZI®

Posted on 2.19.2019

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, J-Code J9173 can be … Read More “AstraZeneca announces new CMS J-code assigned for IMFINZI®”

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

Posted on 1.8.2019

Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. This indication is approved under accelerated approval based on tumor response rate Read More “FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)”

AstraZeneca announces that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code.

Posted on 1.8.2019

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, the following code can … Read More “AstraZeneca announces that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code.”

Astellas Pharma announces FDA approval of XOSPATA.

Posted on 11.30.2018

Astellas Pharma US, Inc. is pleased to announce that the FDA has approved XOSPATA. XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation … Read More “Astellas Pharma announces FDA approval of XOSPATA.”

(FDA) approves a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

Posted on 11.19.2018

On November 16, 2018, the U.S. Food and Drug Administration (FDA) approved a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.

The new indication is as follows:

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma
Read More “(FDA) approves a label change for ADCETRIS® (brentuximab vedotin) for injection, for intravenous use.”

IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Posted on 11.16.2018

AstraZeneca is pleased to announce that IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after January 1, 2019, the following code can … Read More “IMFINZI® (durvalumab) injection has been assigned a unique HCPCS code by the Centers for Medicare & Medicaid Services (CMS).”

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients With Hepatocellular Carcinoma (HCC)

Posted on 11.16.2018
Merck is pleased to announce that KEYTRUDA has been approved by the FDA for the treatment of patients with HCC who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and
Read More “FDA-Approved Indication for KEYTRUDA® (pembrolizumab) for the Treatment of Adult Patients With Hepatocellular Carcinoma (HCC)”

FDA-Approved Indication for KEYTRUDA® (pembrolizumab) Announced

Posted on 11.9.2018

Merck is pleased to announce that KEYTRUDA in combination with carboplatin and either paclitaxel or nab-paclitaxel has been approved by the FDA for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA is also indicated in combination with pemetrexed … Read More “FDA-Approved Indication for KEYTRUDA® (pembrolizumab) Announced”

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Posted on 11.5.2018

Pfizer Inc. (NYSE:PFE) announced 11-5-18 that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease … Read More “U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC”